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Abstract Congenital diaphragmatic hernia (CDH) is a
major life-threatening cause of respiratory failure in the
newborn. Recent data reveal the role of a retinoid-signaling
pathway disruption in the pathogenesis of CDH. We
describe the epidemiology and pathophysiology of human
CDH, the metabolism of retinoids and the implications of
retinoids in the development of the diaphragm and lung.
Finally, we describe the existing evidence of a disruption
of the retinoid-signaling pathway in CDH.
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Introduction
Congenital diaphragmatic hernia (CDH) remains the most
life-threatening cause of severe respiratory failure in the
term infant [1]. Its incidence is 1 in 2,500 births and
accounts for about 8% of major congenital anomalies [2].
Approximately 80% are left-sided defects and the majority
occurs as an isolated anomaly. CDH may, however, also be
associated with a chromosomal abnormality including tri-
somy 13 and 18, Pallister–Killian syndrome and Fryns
syndrome among others. Other associated malformations
include congenital heart disease, spina biﬁda, hydrocephaly
and urological anomalies [3]. Mortality in such cases may
be as high as 90%, many fetuses succumbing in the ante-
natal period. Mortality in isolated CDH has been reported
to range from 20 to 60% mainly because of the differences
in case selection [4, 5]. Recent studies have emphasized the
‘‘hidden mortality’’ in CDH, showing survival of approxi-
mately 40% if all cases of CDH are included from the time
of antenatal diagnosis [1, 5].
Despite remarkable progress in resuscitation and inten-
sive care, the morbidity and mortality rates in CDH remain
high due to severe pulmonary hypoplasia and persistent
pulmonary hypertension resulting from the abnormal
development of the pulmonary vascular bed. Postnatal
therapies such as extracorporeal membrane oxygenation,
inhaled nitric oxide, surfactant and high-frequency venti-
lation have had limited impact on prognosis and survivors
of CDH commonly face considerable morbidity [6, 7].
Prenatal treatments have also been tried in CDH: open fetal
diaphragmatic repair has not showed survival beneﬁt [8]
and a randomized controlled trial on fetoscopic tracheal
occlusion has not shown to be beneﬁcial [9]. Recently, a
randomized study in the use of corticosteroids in late ges-
tation in CDH has shown no beneﬁt [10]. The disappointing
effects of the studied treatments have stimulated studies
aiming at revealing the exact etiopathology of CDH.
Pathophysiology
The classical hypothesis is that the clinical picture in CDH
results from a failed closure of the pleuroperitoneal canals
between the eighth and tenth week of gestation. It was
believed that the associated pulmonary hypoplasia was
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tion of abdominal viscera into the thorax [11].
Nitrofen (2,4-dichlorophenyl-p-nitropheniyl ether) is an
herbicide that has been used for many years to create a
teratogenic animal model of CDH [12]. Nitrofen has a low
toxicity in adult rodents but its administration to pregnant
rodents between day 8 and 11 after conception results in a
high rate of CDH, associated pulmonary hypoplasia and
pulmonary vascular abnormalities to their embryos, all
remarkably similar to the human malformation [12]. The
advantage of this model is that the defect is induced at the
stage when the foregut has just separated into the esopha-
gus and trachea, this model of CDH has given the
opportunity of carefully studying the developmental anat-
omy of the lungs and diaphragm in CDH. Studies in the
Nitrofen model of CDH have showed that hypoplasia of the
lung develops early in gestation, before the normal closure
of the diaphragm takes place [13]. These data led to the
concept of a ‘‘dual-hit hypothesis’’. This hypothesis
explains pulmonary hypoplasia by two developmental
insults. The ﬁrst insult is caused by nitrofen and affects
both lungs before diaphragm development. The second
insult affects the ipsilateral lung after defective diaphragm
development due to the compression of the lung by her-
niated viscera. Moreover, in a ﬁbroblast growth factor 10
(FGF 10) null mutant mice which exhibit bilateral lung
agenesis, Babiuk et al. [14] demonstrated that the dia-
phragm forms normally independently of lung
development and defects in the diaphragm are induced in
the absence of lung tissue. The same authors have dem-
onstrated that the origin of the diaphragmatic defect lies in
the amuscular mesenchymal precursor cells of the dia-
phragm, which are derived from the pleuroperitoneal folds.
This theory is based on the observation that while migra-
tion of muscular precursors is not disturbed, a defect occurs
in regions of the underlying mesenchymal substratum of
the pleuroperitoneal folds [15].
Retinoids metabolism
Retinoids are the family of molecules derived from vitamin
A, which are essential for growth, development and dif-
ferentiation [16]. Vitamin A is obtained from the diet in the
form of retinyl esters present in animal meat or b-carotene
present in vegetables. After absorption through the gut,
retinyl esters are transported in chylomicrons to the liver
for storage, where they are metabolized into retinol
(Fig. 1). To meet tissue needs for retinol, livers secrete
retinal bound to retinol-binding protein (RBP) into plasma,
where it forms the main transporting complex with trans-
thyretin. Circulating retinol binds to cell surface receptors
and is internalized into target cells. Within the cytoplasm,
retinol can be either oxidized to retinal or esteriﬁed to
retinyl esters by lecitin retinol acetyltransferase (LRAT)
for storage (Fig. 1). If converted to retinal, retinol is bound
to cellular retinol binding protein I (CRBP-I) and is con-
verted into retinal by retinol dehydrogenase (ROLDH)
followed by a further dehydrogenation to retinoic acid
(RA) using four cytosolic retinal dehydrogenases
(RALDH). Although there are three known retinal dehy-
drogenases, RALDH1, RALDH2, and RALDH3, RALDH2
has a predominant role in generating retinoic acid. Retinoic
acid is the biologically active metabolite of retinoids. Once
retinoic acid has been synthesized in the cell, it enters the
nucleus and binds to two ligand-activated nuclear tran-
scription factors known as retinoic acid receptors (RARs)
and retinoid X receptors (RXRs). There are three members
of each class of receptor and these are known as a, b, and c,
thus giving a RARa, RARb and RARc and RXRa, RXRb
and RXRc. To act on a responsive gene, one of the RARs
heterodimerises with one of the RXRs. The RAR–RXR
heterodimers are the functional units in transducing the
retinoid signal at the gene level. Retinoic acid is further
metabolized to inactive compounds by the action of Cyp26
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Fig. 1 Overview of the retinoid-signaling pathway. After absorption
through the gut, retinyl esters are transported in chylomicrons to the
liver for storage, where they are metabolized into retinol. To meet the
tissue needs for retinoids, the liver secretes retinol bound to the retinol
binding protein (RBP) into the plasma, where it forms the main
transporting complex with transthyretin (TTR). Within the cell
cytoplasm, retinol is bound to cellular retinol biding protein (CRBP).
Retinol can be either oxidized to retinal by an alcohol dehydrogenase
(ROLDH) or esteriﬁed to retinyl esters by lecitin retinol acetyltrans-
ferase (LRAT) for storage. Retinal dehydrogenase (RALDH) then
converts retinal to retinoic acid (RA). Retinoic acid exerts its
biological effects through binding nuclear receptors, the retinoic acid
receptors (RAR) heterodimerizes with the retinoid X receptors (RXR)
to initiate transcription. In the cytoplasm, Cyp26 enzyme breaks down
retinoic acid into inactive metabolites. It has been reported that LRAT
activity could also be regulated by retinoic acid concentration
756 Pediatr Surg Int (2008) 24:755–761
123enzyme, a newly recognized member of the cytochrome
P450 family [16].
Retinoids and the development of lung and diaphragm
Mammalian lung development can be divided into ﬁve
overlapping phases: embryonic, pseudoglandular, canalic-
ular, saccular and alveolar period. Retinoids play an
important role in each of the lung developmental stages.
The human lung originates in the 3-week-old embryo as a
ventral diverticulum that arises from the foregut. This
endodermal bud grows caudally to form the trachea and
then divides to form the two primary lung buds. By
continuing dichotomous divisions, the two lung buds con-
tinue to form the bronchopulmonary segments of the
mature lung. The structure of these buds consists of a
columnar endoderm surrounded by splachnic mesoderm.
By the sixth week of gestation, the pulmonary blood supply
has connected to the developing heart [17]. Under condi-
tions of acute maternal retinol deﬁciency, embryos display
agenesis of the lung buds [18]. Retinoic acid biosynthesis
and expression of RALDH2 are detected throughout the
layers where the trachea and primitive lungs are forming
[19]. CRBPs and retinoid receptors (RARb, RXRa and b)
are expressed in the early phases of lung formation [20,
21]. Using BMS493, a retinoic acid receptor antagonist
(RARa, b and c), mice embryos show no evidence of lung
buds [22]. It has been demonstrated that a major role for
retinoic acid in early lung morphogenesis is to selectively
maintain mesodermal proliferation and induce ﬁbroblast
growth factor 10 expression in the foregut region in the
initial budding of the lungs from the foregut [23].
The pseudoglandular stage of lung development occurs
in the human between the seventh and sixteenth week of
gestation [17]. During this period, conducting airways are
formed by repeated dichotomous branching of the devel-
oping epithelium into the sorrounding mesenchyme.
During this phase, the lung has a distinctly glandular
appearance. By the 16th week of gestation, all bronchial
airways have been formed. After this time, further growth
occurs only by elongation and widening of existing airways
and not by further branching [17]. As the developing lung
begins this phase, RARs and RXRs continue to be
expressed. RARa, RARc, RXRa, RXRb and RXRc are
present throughout the epithelium and mesenchyme at both
proximal and distal sites. RARb is present in proximal cells
and in the distal mesenchyme but not in the distal epithe-
lium [18]. RALDH2 expression is downregulated in
regions of the lung that are undergoing budding and
remains high in proximal regions of the lobes. Coinci-
dently, a proximodistal gradient of CYP26, the enzyme that
catabolizes retinoic acid, is established, with highest levels
in distal buds. This may imply that during the pseudo-
glandular stage of lung development, retinoic acid may
inhibit distal branching morphogenesis and act as a dif-
ferentiating agent for proximal buds [18].
The canalicular phase of lung development takes place
from the 16th to 26th week of gestation. This phase is
characterized by the appearance of acini, consisting of an
airway stem and a spray of short tubules arranged in a
cluster surrounded by a covering of loose and thin mes-
enchyme. The mesenchyme becomes riddled with
capillaries and is said to be ‘‘canalized’’. The epithelial
cells lining the tubules in the distal regions of the lung
begin to ﬂatten out and differentiate into type I and type II
pneumocytes. At the end of this phase, gas exchange in the
26–28th week human can be supported. During this period,
RARb, RXRa and RXRb are associated with epithelial cell
differentiation and structural changes [18].
The saccular phase of lung development takes place
from 24 weeks of gestation until term and is associated
with striking changes in the appearance of the lung. There
is a marked decrease of the prominence of interstitial tissue
and a marked thinning of the airspace walls. Tissue pro-
jections into the distal airspace divide the distal airspaces
into saccules. The cells lining the saccules of human fetal
lung at this stage of development are recognizable type I
and type II pneumocytes. Type II cells produce surfactant
and are regarded as a lung progenitor cell population for
type I cell [24]. During this period, retinoic acid stimulates
proliferation of type II cells through an epithelial growth
factor-mediated pathway [25]. Consistent results indicate
that retinoic acid stimulates phospholipids synthesis, but
there are considerable contradictory data on the effects of
retinoic acid on surfactant protein production [18].
RALDH1 and RALDH2 are signiﬁcantly upregulated
during this period [26]. RALDH1 mRNA is expressed in
the bronchial epithelium and alveolar interstitial tissue.
RALDH2 mRNA is expressed in the bronchial epithelium
and pleura, supporting the idea that RALDH2 could act as
a local developmental signal to induce the distal formation
of alveoli.
The alveolar period starts around the 36th week of
gestation and continues postnatally, probably terminating
by 18 or 24 months [27]. Alveolization starts with the
appearance of crests along the sides of the saccular walls,
which grow and divide the saccules into smaller units, the
alveoli. The gas-exchange area therefore increases sub-
stantially while the mean alveolar size decreases. Two
populations of ﬁbroblasts are present in the alveolar wall.
In one population there are abundant lipid droplets, the
lipid interstitial ﬁbroblasts, which synthesize and secrete
retinoic acid [28]. The other population is the non-lipid
interstitial ﬁbroblasts. Together these cells are the major
contributors to the synthesis of the extracellular matrix,
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exchanging surface [29]. Ultrastructural analysis has
demonstrated that the lipid interstitial ﬁbroblasts are in
close contact with type II cells and that type II cells may be
involved in the eruption of secondary septa [30]. Strong
evidence for a role of retinoids in alveologenesis comes
from a study from Massaro and Massaro [31]. These
authors demonstrated a 50% increase in alveolar number
along with a reduction in their size if retinoic acid was
given to newborn mice. Moreover, recent data suggest that
retinoic acid can induce alveolar regeneration in the adult
mouse lung [32]. The function of the individual receptors
during alveologenesis has been deduced from the pheno-
types of the receptors knockouts. In postnatal RARc -/-
mice, the lungs contained less elastin and there was a
decrease in alveolar wall volume density, alveolar surface
area and number of alveoli [33]. RARa -/- postnatal
mice, by contrast, had normal alveoli. But by day 50,
alveolar volumes were higher, there were fewer alveoli and
the alveolar surface area was lower [34]. This demonstrated
that RARa plays a role in the continuing process of alve-
ologenesis. The role of RARb is even more surprising in
that the alveolar volumes of RARb -/- postnatal mice are
smaller, there are more alveoli and the alveolar surface area
is larger [35]. This suggests that RARb is an endogenous
inhibitor of alveolar septation.
According to the classical view, the diaphragm is
formed from the septum transversum that separates the
thoracic and abdominal cavities and leaves two pleuro-
peritoneal canals dorsally. By the 7th week of gestation,
pleuroperitoneal folds extend from the lateral body wall
and grow ventrally to fuse with the posterior margin of the
septum transversum, thus sealing off the pleuroperitoneal
canals. The deﬁnitive musculotendinous diaphragm incor-
porates muscle derivatives from four embryonic structures:
the septum transversum, the pleuroperitoneal folds, the
paraxial mesoderm of the body wall and the esophageal
mesenchyme [36]. More recent embryological studies in
the Nitrofen model of CDH have identiﬁed the pleuroper-
itoneal folds as the primary source of diaphragmatic
musculature [37]. The pleuroperitoneal folds are derived
from mesenchymal cells migrating from the somatic
mesoderm. After that, muscle precursors migrate from the
dermomyotome of cervical somites and localize in the
pleuroperitoneal folds from where they migrate and from
the lateral aspect of the septum transversum to the body
wall and from the esophageal mesentery to the dorsal
aspects of the crural region. The phrenic nerve makes
contact with pleuroperitoneal folds, it trifurcates and
extends intramuscular branches to the central, dorsolateral
and crural areas of the developing diaphragm [38].
RALDH2 and RBP are strongly expressed in the pleuro-
peritoneal folds at postconceptional day 13 in rat [39, 40].
RARb transcripts, but not RARc transcripts are expressed
in the rat diaphragm at postconception day 12.5 suggesting
that RARb could play a role in its formation [41].
Existing evidence of the role of retinoids in CDH
The ﬁrst evidence linking retinoids with CDH came from
examination of pups born to rat dams bred on a Vitamin A
deﬁcient diet. Diaphragmatic hernias were present in 25–
70% of the offspring of Vitamin A deﬁcient dams, the
majority of them being right sided CDH [42, 43]. The rate
of herniation was decreased when Vitamin A was intro-
duced into the diet, being totally prevented if Vitamin A
was given on days 10th and 11th of gestation [42].
Studies on retinoic acid receptors double knockout mice
have demonstrated that some offspring have CDH. Inter-
estingly, RAR ab2 double mutant had right-sided defects,
whereas RAR ab2+/- double mutant had left-sided defects
[41].
To date, there is only one clinical study linking retinoids
to CDH [44]. Retinol and RBP were measured in 11
healthy newborns and in 11 CDH affected newborns. Both
markers were decreased by 50% in cord blood of newborns
with CDH when compared to newborns without CDH.
Conversely, both retinol and RBP were signiﬁcantly
increased in the mothers of affected infants suggesting a
possible deterioration of retinol transport across the pla-
centa [44]. There is an ongoing multicenter international
study aiming at measuring the retinoids state in mothers
and newborn with CDH in a large cohort of patients
(communication at the Congenital Diaphragmatic Hernia
Work Study Group meeting, Houston, October 2007).
The largest evidence for the role of retinoids in CDH
comes from the nitrofen model of CDH. The pathogenic
mechanism of nitrofen, long unknown, has recently been
clariﬁed by Noble et al. [45]. These authors tested the three
hypothesis regarding nitrofen’s mechanism of action: they
examined the interaction of nitrofen with various aspects of
the retinoid signaling pathway, examined the interaction of
nitrofen and vitamins A, C and E to test the hypothesis that
nitrofen was functioning as an antioxidant to interfere with
retinoid signaling. Finally, they studied the interaction of
nitrofen and thyroid signaling to test the hypothesis that
because there are stereochemical similarities between the
structure of nitrofen and thyroid hormone, nitrofen could
alter thyroid hormone and thyroid hormone receptor
functions. They concluded that nitrofen induces a marked
decrease in retinoic acid levels, most probably due to
inhibition of RALDH function rather than expression, since
RALDH mRNA levels were normal. Retinoic acid syn-
thesis perturbations did not appear to involve oxidative
effects, neither perturbations of thyroid hormone signaling
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sistent with previous biochemical data showing nitrofen
suppression of RALDH2 activity [40].
The hypothesis that nitrofen disrupts the retinoid-sig-
naling pathway was ﬁrst tested using genetically
engineered mice that had the lacZ reporter gene linked to a
retinoic response element (RARE). There was a pro-
nounced suppression of RARE-lacZ expression by nitrofen
in in vitro whole embryo culture and in in vivo mouse
model [46]. Further, the nitrofen-induced suppression was
antagonized by supplemental administration of retinoic
acid. Thebaud et al. [47] demonstrated that coadministra-
tion of large doses of Vitamin A along with nitrofen can
reduce the incidence of CDH in the offpring from 84 to 20–
40% depending on the day Vitamin A was given. They also
demonstrated that Vitamin A could attenuate lung hypo-
plasia. These results were later conﬁrmed by other
investigators [48, 49]. Moreover, Babiuk et al. [50] dem-
onstrated that the incidence of CDH is dramatically
reduced from 54 to 8% if retinoic acid is given to pregnant
rats along with nitrofen. The partial reduction in the inci-
dence of nitrofen-induced CDH by the administration of
large doses of Vitamin A is consistent with the hypothesis
that the decreased enzyme activity can be partially coun-
tered by increasing the amount of substrate. Administration
of retinoic acid bypasses the enzymatic alteration and
explains the marked increase in efﬁcacy of CDH reduction
[50].
Nakazawa et al. have studied in depth the effects of
nitrofen on the retinoid-signaling pathway. They demon-
strated that there is a downregulation of Cyp26 and LRAT,
meaning that retinoic acid is decreased in nitrofen-induced
hypoplastic lungs [51]. However, they also demonstrated
that lung retinol storage is decreased whereas serum retinol
levels were signiﬁcantly higher in the nitrofen model of
CDH. Moreover, gene expression of most of the down-
stream components of the retinoid-signalling pathway,
except for RALDH2, were increased in this model, sug-
gesting a possible feedback reaction to the deﬁciency of
lung retinol and that nitrofen may act by interfering with
the cellular uptake of retinol during lung morphogenesis,
resulting in pulmonary hypoplasia in this model [52].
Retinoids have also been used as a possible treatment in
the nitrofen model of CDH. We showed that retinoic acid
improves nitrofen-induced hypoplastic lung growth using
fetal lung rat explants [53]. These results suggested that
retinoid pathway might be involved not only in the path-
ogenesis of the diaphragmatic defect but also in the
pathogenesis of associated pulmonary hypoplasia. We have
recently demonstrated by means of stereological measure-
ments and DNA content quantiﬁcation, that retinoic acid
promotes pulmonary alveologenesis in vivo at the end of
gestation in the nitrofen model of CDH [54]. Moreover,
Sugimoto et al. [55] have demonstrated that this is proba-
bly due to acceleration of type I alveolar cell proliferation
of the hypoplastic lung in the nitrofen model of CDH.
Collectively, all these data strongly imply that CDH is
caused by an interference with the retinoid-signalling
pathway. If these experimental data are demonstrated in the
human, retinoids may be used as an alternative therapeutic
approach aimed at improving lung growth antenatally.
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